Alpha-melanocyte stimulating hormone (University of Texas)

LONGJUMEAU, France, Nov. 29, 2022 /PRNewswire/ -- TargEDys and SymbioPharm signed an exclusive marketing and distribution agreement for the launch of SymbioLife® Satylia® in Germany. The novel dietary supplement based on the next-generation probiotic Hafnia alvei HA4597 will be available from January 2023. SymbioLife® Satylia® is a precision probiotic with a characterized mechanism of action at molecular level: it increases satiety thanks to the protein ClpB produced by Hafnia alvei HA4597. ClpB naturally mimics the human satiety hormone alpha-MSH. The improved feeling of satiety helps with successful weight loss, as confirmed by a clinical study with 230 overweight adults. This natural principle provided by SymbioLife ® Satylia ® is a multi-awarded new, natural, safe and effective weight management solution. Grégory Lambert, CEO of TargEDys: "We are extremely proud and excited about this new collaboration. SymbioPharm is in the top 3 of the German probiotics market and fathered one of the first probiotic pharmaceuticals globally. With the team's knowledge of probiotic Enterobacteria, their strong position with doctors, pharmacies, and synergies with probiotics and diagnostics, they are the perfect partner for this highly scientific product." Juergen Eck, Co-CEO and CTO of SymbioPharm: "We are very excited to partner with TargEDys and work together on a new era of evidence-based probiotics. With the patent-protected probiotic Hafnia alvei HA4597, its biological mechanism of action and outstanding studies, we can offer an effective solution for the growing problems of obesity and metabolic health. As pioneers in microbiome research and medical probiotics, we are proud to now also help shape the introduction of knowledge-based precision probiotics." About SymbioPharm SymbioPharm GmbH is a pioneer in microbiome research and knowledge-based probiotics - since 1954. Its mission is to preserve health and to heal diseases with probiotic bacteria – making use of purely biological effect of natural bacteria. Therefore, it researches the human microbiome and develops innovative microbiological therapy approaches. The company holds a state-of-the-art production facility, and showcases comprehensive expertise from diagnostics – with the Institute for Microecology – to innovative solutions. About TargEDys® TargEDys® is a commercial-stage French biotech specialized in the development of nutraceutical solutions through microbiome interventions. The company is based on 15 years of research on the microbiota conducted within academic laboratories. TargEDys®' portfolio focuses on overweight, undernutrition, and mental health, all based on the concept of PreciBiomic strains backed by a molecular mechanism of action and in vivo studies. Contact: Arnaud Faure & Nina Vinot [email protected] Logo - SOURCE TargEDys

LONGJUMEAU, France, Sept. 27, 2022 /PRNewswire/ -- TargEDys and Inoliva, an affiliate of Abdi Ibrahim, have signed an exclusive marketing and distribution agreement to bring Satylia, a food supplement based on the next-generation probiotic Hafnia alvei HA4597, to the Turkish market. Satylia, also called EnteroSatys in other markets, is a precision probiotic with a characterized mechanism of action at molecular level: it increases feelings of fullness thanks to the probiotic's protein ClpB that mimics the satiety hormone alpha-MSH. Its efficacy was demonstrated in a clinical trial involving 230 overweight adults. It is a new, natural, safe, and effective solution to weight management and a multi-award winner. Turkey has a population of 85 million and is the highest-ranking country in Europe for obesity and overweight. Grégory Lambert, CEO of TargEDys: "We are thrilled about this new collaboration. Inoliva, with its premium and scientific positioning, backed by the superb pharmaceutical establishment of Abdi Ibrahim, is the best possible partner for Satylia!" Aslı Biçer, General Manager of Inoliva: "The weight management category has a volume growth of 76% in Turkey, due to a growing number of people with obesity and increasing awareness on healthy living. We wanted to exist in this market with a clinically-proven, natural, side-effect-free and sustainable solution. Satylia is exactly what we were looking for. Our goal is to improve the eating habits of consumers and become #1 choice among weight management brands." About Inoliva and Abdi Ibrahim Inoliva is a pioneering pharmaceutical company formed under the leadership of experienced specialists, driven by the mission to provide the public with access to revolutionary products that aid in the preservation of life. The strategy of Inoliva is multi-channel with a focus on dieticians, a strong relationship with the pharmacist's network, combined with a DTC promotion. Abdi Ibrahim, the leading pharmaceutical company in Turkey, acquired 90% of Inoliva's shares in 2021 and will focus on growth in consumer healthcare and biotechnology in future years. About TargEDys® TargEDys® is a commercial-stage French biotech specialized in the development of nutraceutical solutions through microbiome interventions. The company is based on 15 years of research on the microbiota conducted within academic laboratories. TargEDys® develops a product portfolio focusing on overweight, undernutrition, and mental health, all based on the concept of PreciBiomic strains backed by a molecular mechanism of action and in vivo studies. CONTACT: Arnaud Faure & Nina Vinot ; [email protected] Logo - SOURCE TargEDys; Inoliva